Login

Join for Free!
18528 members
Home Forum Dictionary Articles Tutorials Books Directory Share your work
table of contents table of contents

The article discusses several models, with a focus on how they have …

Biology Articles » Biomathematics » Molecular biology of breast metastasis: The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer » References

References
- Molecular biology of breast metastasis: The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer

1.   Bailar JC III, Gornik HL: Cancer undefeated.
N Engl J Med 1997, 336:1569-1574.
   
 
2.   Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999.
CA Cancer J Clin 1999, 49:8-31.
   
 
3.   Early Breast Cancer Trialists' Collaborative Group: : Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
Lancet 1992, 339:71-85.
   
 
4.   Brinkley D, Haybittle JL: The curability of breast cancer.
World J Surg 1977, 1:287-289.
   
 
5.   Brinkley D, Haybrittle JL: The curability of breast cancer.
Lancet 1975, 2:95-97.
   
 
6.   Duncan W, Kerr GR: The curability of breast cancer.
Br Med J 1976, 2:781-783.
   
 
7.   Easson EC, Russell MH: .
Curability of Cancer in Various Sites: 4th Statistical Report. Baltimore: Williams & Wilkins, 1968. OpenURL
   
 
8.   Pocock SJ, Gore SM, Kerr GR: Long term survival analysis: the curability of breast cancer.
Stat Med 1982, 1:93-104.
   
 
9.   Karrison TG, Ferguson DJ, Meier P: Dormancy of mammary carcinoma after mastectomy.
J Natl Cancer Inst 1999, 91:80-85.
   
 
10.   Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy.
J Clin Oncol 1996, 14:2738-2746.
   
 
11.   Skipper HE: On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).
Bull Math Biol 1986, 48:253-278.
   
 
12.   Retsky MW, Demicheli R, Swartzendruber DE, Bame PD, Wardwell RH, Bonadonna G, Speer JF, Valagussa P: Computer simulation of a breast cancer metastasis model.
Breast Cancer Res Treat 1997, 45:193-202.
   
 
13.   Speer JF, Petrosky VE, Retsky MW, Wardwell RH: A stochastic numerical model of breast cancer growth that simulates clinical data.
Cancer Res 1984, 44:4124-4130.
   
 
14.   Norton L, Simon R: The Norton-Simon hypothesis revisited.
Cancer Treat Rep 1986, 70:163-169.
   
 
15.   Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules.
Cancer Treat Rep 1977, 61:1307-1317.
   
 
16.   Norton L, Simon R: Growth curve of an experimental solid tumor following radiotherapy.
J Natl Cancer Inst 1977, 58:1735-1741.
   
 
17.   Spratt JA, von Fournier D, Spratt JS, Weber EE: Decelerating growth and human breast cancer.
Cancer 1993, 71:2013-2019.
   
 
18.   Spratt JA, von Fournier D, Spratt JS, Weber EE: Mammographic assessment of human breast cancer growth and duration.
Cancer 1993, 71:2020-2026.
   
 
19.   Koscielny S, Tubiana M, Valleron AJ: A simulation model of the natural history of human breast cancer.
Br J Cancer 1985, 52:515-524.
   
 
20.   Norton L, Simon R, Brereton HD, Bogden AE: Predicting the course of Gompertzian growth.
Nature 1976, 264:542-545.
   
 
21.   Bloom HJG, Richardson WW, Harries EJ: Natural history of untreated breast cancer (1805-1933) comparison of untreated and treated cases according to histogical grade of malignancy.
Br Med J 1962, 2:213-221. OpenURL
   
 
22.   Sullivan PW, Salmon SE: Kinetics of tumor growth and regression in IgG multiple myeloma.
J Clin Invest 1972, 51:1697-1708.
   
 
23.   Heuser L, Spratt J, Polk H: Growth rates of primary breast cancer.
Cancer (Phil) 1979, 43:1888-1894. OpenURL
   
 
24.   Retsky MW, Swartzendruber DE, Wardwell RH, Bame PD: Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?
Med Hypotheses 1990, 33:95-106.
   
 
25.   Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.
Nature Med 1995, 1:149-153.
    Ret
 
26.   Folkman J: New perspectives in clinical oncology from angiogenesis research.
Eur J Cancer 1996, 32A:2534-2539.
   
 
27.   Folkman J: Fighting cancer by attacking its blood supply.
Sci Am 1996, 275:150-154.
   
 
28.   Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease.
Nature Med 1995, 1:27-31.
   
 
29.   Norton L: A Gompertzian model of human breast cancer growth.
Cancer Res 1988, 48:7067-7071.
   
 
30.   Retsky M, Swartzendruber D, Wardell R, Bame P, Petrosky V: Re: Larry Norton, a Gompertzian model of human breast cancer growth [letter; comment].
Cancer Res 1989, 49:6443-6444.
   
 
31.   Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S: Report of the International Workshop on Screening for Breast Cancer [see comments].
J Natl Cancer Inst 1993, 85:1644-1656.
   
 
32.   Skipper HE, Schabel FM Jr, Wilcox WS: Experimental evaluation of potential anticancer agents: XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia.
Cancer Chemother Rep 1964, 35:1-111.
   
 
33.   Luria SE, Delbruck M: Mutations of bacteria from virus sensitivity to virus resistance.
Genetics 1943, 28:491-511. OpenURL
   
 
34.   Law LW: Origin of the resistance of leukaemic cells to folic acid antagonists.
Nature 1952, 169:628-629.
     
 
35.   Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
Cancer Treat Rep 1979, 63:1727-1733.
   
 
36.   Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy.
Cancer Treat Rep 1982, 66:439-449.
   
 
37.   Panetta JC: A mathematical model of drug resisitance: heterogeneous tumors.
Math Biosci 1998, 147:41-61.
   
 
38.   Retsky MW, Swartzendruber DE, Bame PD, Wardell RH: Computer model challenges breast cancer treatment strategy.
Cancer Invest 1994, 12:559-567.
   
 
39.   Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G: Proposal for a new model of breast cancer metastatic development.
Ann Oncol 1997, 8:1075-1080.
   
 
40.   Swartzendruber DE, Retsky MW, Wardwell RH, Bame PD: An alternative approach for treatment of breast cancer.
Breast Cancer Res Treat 1994, 32:319-325.
     
 
41.   Demicheli R, Miceli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Valagussa P, Bonadonna G: Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'.
Breast Cancer Res Treat 1999, 53:209-215.
   
 
42.   Buzzoni R, Bonadonna G, Valagussa P, Zambetti M: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
J Clin Oncol 1991, 9:2134-2140.
   
 
43.   International Breast Cancer Study Group: : Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group.
J Clin Oncol 1996, 14:1885-1894.
   

rating: 0.00 from 0 votes | updated on: 19 Dec 2006 | views: 1236 |

share this article | email to friends

suggest a revision
print this page
print the whole article

Rate article:







excellent!bad…